Granules India may find a buyer in a large private equity firm Carlyle Group. It has been active on pharma investment, three independent sources shared with CNBC-TV18.
They suggested that Carlyle is in advanced stages to acquire Granules India for $1 billion approximately. Carlyle expects to buy promoter shares which leads to an open offer to acquire the additional stakes from others.
Carlyle acquired Sequent Scientific and bought a minority stake in Piramal Pharma. Granules India has been exploring options to sell stake due to favourable valuations and succession issues. The company predominates is active in pharmaceutical ingredients and contract research and manufacturing.
Both companies have declined to comment on the matter.
